

Supplementary Table 1. League table

(A)

EPI-LSE																
0.25 (0.02,2.76)	AV+sLS															
0.24 (0.03,2.20)	0.93 (0.09,9.91)	AV+iLS														
0.25 (0.02,3.13)	0.98 (0.07,13.90)	1.05 (0.08,13.05)	AV+AE-sLS													
0.15 (0.02,0.99)	0.59 (0.08,4.57)	0.63 (0.10,4.11)	0.60 (0.07,4.86)	AV+AE-pv												
0.16 (0.02,1.52)	0.65 (0.06,6.84)	0.69 (0.08,6.30)	0.66 (0.07,6.59)	1.10 (0.20,5.98)	AV+AE-iLS											
0.13 (0.05,0.36)	0.53 (0.06,4.60)	0.57 (0.08,4.18)	0.54 (0.05,5.54)	0.89 (0.18,4.46)	0.82 (0.11,5.96)	AV+SR										
0.10 (0.01,0.81)	0.40 (0.04,3.68)	0.43 (0.05,3.36)	0.41 (0.05,3.53)	0.68 (0.15,3.04)	0.62 (0.10,3.68)	0.76 (0.12,4.69)	AV+AE-cLS									
0.05 (0.01,0.35)	0.21 (0.03,1.63)	0.23 (0.04,1.47)	0.22 (0.02,1.98)	0.36 (0.09,1.50)	0.33 (0.05,2.08)	0.41 (0.08,1.98)	0.54 (0.10,2.83)	ENS								
0.05 (0.01,0.31)	0.20 (0.03,1.45)	0.22 (0.04,1.29)	0.21 (0.02,1.78)	0.34 (0.09,1.29)	0.31 (0.05,1.84)	0.39 (0.09,1.73)	0.51 (0.10,2.49)	0.95 (0.26,3.49)	AV-eLS							
0.05 (0.01,0.40)	0.19 (0.02,1.79)	0.20 (0.02,1.64)	0.19 (0.02,2.03)	0.32 (0.06,1.72)	0.29 (0.04,2.19)	0.35 (0.05,2.31)	0.47 (0.07,3.03)	0.87 (0.16,4.79)	0.92 (0.18,4.72)	AE						
0.05 (0.01,0.27)	0.19 (0.03,1.26)	0.20 (0.04,1.11)	0.19 (0.03,1.19)	0.31 (0.12,0.85)	0.29 (0.07,1.14)	0.35 (0.08,1.47)	0.47 (0.15,1.45)	0.87 (0.26,2.91)	0.91 (0.30,2.75)	1.00 (0.23,4.40)	AV+AE					
0.04 (0.01,0.24)	0.18 (0.03,1.12)	0.19 (0.04,0.98)	0.18 (0.02,1.35)	0.30 (0.10,0.92)	0.27 (0.05,1.36)	0.33 (0.09,1.28)	0.44 (0.11,1.80)	0.82 (0.28,2.39)	0.86 (0.32,2.35)	0.94 (0.23,3.95)	0.95 (0.41,2.18)	CTR				
0.04 (0.01,0.21)	0.17 (0.03,0.99)	0.18 (0.04,0.86)	0.17 (0.02,1.23)	0.28 (0.10,0.79)	0.26 (0.05,1.22)	0.32 (0.09,1.09)	0.42 (0.11,1.60)	0.78 (0.29,2.09)	0.82 (0.35,1.90)	0.90 (0.22,3.65)	0.90 (0.44,1.83)	0.95 (0.56,1.60)	AV			
0.03 (0.00,0.40)	0.12 (0.01,1.78)	0.13 (0.01,1.67)	0.12 (0.01,2.03)	0.20 (0.02,1.95)	0.18 (0.01,2.33)	0.22 (0.02,2.46)	0.29 (0.03,3.35)	0.54 (0.06,5.34)	0.57 (0.06,5.33)	0.62 (0.07,5.37)	0.63 (0.07,5.43)	0.66 (0.08,5.36)	0.70 (0.09,5.52)	RTx		
0.02 (0.00,0.15)	0.09 (0.01,0.68)	0.09 (0.01,0.61)	0.09 (0.01,0.83)	0.15 (0.03,0.63)	0.14 (0.02,0.87)	0.17 (0.03,0.84)	0.22 (0.04,1.19)	0.41 (0.12,1.37)	0.43 (0.11,1.64)	0.47 (0.08,2.64)	0.47 (0.14,1.64)	0.50 (0.17,1.47)	0.53 (0.19,1.47)	0.75 (0.08,7.53)	AV-ENS	
0.01 (0.00,0.07)	0.03 (0.00,0.33)	0.04 (0.00,0.30)	0.03 (0.00,0.38)	0.06 (0.01,0.32)	0.05 (0.01,0.42)	0.06 (0.01,0.42)	0.09 (0.01,0.58)	0.16 (0.03,0.88)	0.17 (0.03,0.86)	0.18 (0.03,1.01)	0.18 (0.04,0.86)	0.19 (0.05,0.78)	0.20 (0.05,0.84)	0.29 (0.04,2.39)	0.39 (0.07,2.17)	SR

(B)

EPI-LSE

0.21 (0.03,1.28)	AV+AE-pV														
0.21 (0.03,1.37)	1.01 (0.19,5.36)	AV+ILS													
0.17 (0.02,1.38)	0.84 (0.13,5.50)	0.84 (0.12,5.79)	AV+sLS												
0.12 (0.05,0.28)	0.59 (0.12,2.98)	0.58 (0.11,3.17)	0.70 (0.10,4.65)	AV+SR											
0.12 (0.01,0.97)	0.56 (0.08,3.91)	0.56 (0.08,4.11)	0.67 (0.08,5.85)	0.96 (0.13,6.79)	VZVIG										
0.06 (0.01,0.54)	0.27 (0.03,2.19)	0.27 (0.03,2.29)	0.32 (0.03,3.23)	0.46 (0.06,3.80)	0.48 (0.05,4.63)	SR									
0.05 (0.01,0.26)	0.25 (0.06,0.98)	0.25 (0.06,1.05)	0.30 (0.06,1.59)	0.43 (0.11,1.71)	0.45 (0.08,2.56)	0.93 (0.14,6.28)	AV-eLS								
0.03 (0.01,0.15)	0.17 (0.05,0.53)	0.17 (0.05,0.58)	0.20 (0.05,0.90)	0.29 (0.09,0.93)	0.30 (0.06,1.47)	0.63 (0.11,3.65)	0.68 (0.32,1.43)	AV							
0.03 (0.00,0.37)	0.13 (0.01,1.55)	0.13 (0.01,1.60)	0.16 (0.01,2.21)	0.22 (0.02,2.68)	0.23 (0.02,3.11)	0.48 (0.09,2.58)	0.52 (0.05,5.29)	0.77 (0.09,6.90)	ACTH						
0.03 (0.00,0.15)	0.13 (0.03,0.59)	0.13 (0.03,0.63)	0.15 (0.02,0.94)	0.22 (0.05,1.03)	0.23 (0.04,1.41)	0.48 (0.07,3.47)	0.51 (0.14,1.82)	0.76 (0.27,2.10)	0.98 (0.09,10.51)	ENS					
0.03 (0.01,0.12)	0.13 (0.04,0.45)	0.13 (0.03,0.49)	0.15 (0.03,0.75)	0.22 (0.06,0.79)	0.23 (0.05,1.02)	0.48 (0.09,2.63)	0.52 (0.21,1.28)	0.76 (0.45,1.28)	0.99 (0.12,8.21)	1.01 (0.35,2.86)	CTR				
0.02 (0.00,0.09)	0.09 (0.02,0.35)	0.09 (0.02,0.38)	0.11 (0.02,0.57)	0.16 (0.04,0.61)	0.16 (0.03,0.91)	0.34 (0.05,2.12)	0.37 (0.13,1.03)	0.54 (0.26,1.10)	0.70 (0.07,6.76)	0.71 (0.21,2.46)	0.71 (0.30,1.66)	AV+AE			
0.02 (0.00,0.12)	0.08 (0.01,0.48)	0.08 (0.01,0.51)	0.09 (0.01,0.73)	0.14 (0.02,0.83)	0.14 (0.02,1.11)	0.29 (0.06,1.37)	0.32 (0.07,1.54)	0.47 (0.12,1.88)	0.61 (0.07,5.33)	0.62 (0.11,3.39)	0.61 (0.15,2.54)	0.87 (0.21,3.61)	AE		
0.02 (0.00,0.08)	0.07 (0.02,0.31)	0.07 (0.02,0.33)	0.09 (0.02,0.49)	0.12 (0.03,0.54)	0.13 (0.02,0.74)	0.27 (0.04,1.84)	0.29 (0.09,0.92)	0.43 (0.18,1.03)	0.56 (0.06,5.64)	0.57 (0.20,1.65)	0.57 (0.23,1.39)	0.80 (0.26,2.43)	0.92 (0.18,4.64)	AV-ENS	

(D)

ENS

0.01 (-1.13,1.15)	AV+iLS						
-0.69 (-1.72,0.33)	-0.70 (-2.08,0.67)	AV+AE-sgLS					
-0.96 (-2.05,0.13)	-0.97 (-2.40,0.45)	-0.27 (-1.38,0.84)	AV+AE-iLS				
-1.02 (-1.85,-0.20)	-1.03 (-2.26,0.20)	-0.33 (-1.18,0.52)	-0.06 (-0.98,0.86)	AV+AE-cLSC			
-1.20 (-1.67,-0.73)	-1.21 (-2.24,-0.18)	-0.51 (-1.42,0.40)	-0.24 (-1.22,0.75)	-0.18 (-0.85,0.50)	AV		
-1.23 (-1.89,-0.58)	-1.24 (-2.37,-0.12)	-0.54 (-1.41,0.33)	-0.27 (-1.21,0.67)	-0.21 (-0.82,0.40)	-0.03 (-0.48,0.42)	AV+AE-pv	
-1.66 (-2.38,-0.95)	-1.67 (-2.83,-0.51)	-0.97 (-1.71,-0.23)	-0.70 (-1.53,0.13)	-0.64 (-1.05,-0.23)	-0.46 (-1.00,0.07)	-0.43 (-0.89,0.02)	AV+AE

(E)

AV+iLS

-0.22 (-2.66, 2.22)	AV-sqL																				
-0.75 (-2.66, 1.16)	-0.53 (-2.75, 1.69)	ENS																			
-1.15 (-3.33, 1.02)	-0.93 (-3.38, 1.51)	-0.40 (-2.33, 1.52)	AV+AE-sgLS																		
-1.48 (-3.65, 0.69)	-1.26 (-3.70, 1.18)	-0.73 (-2.65, 1.19)	-0.33 (-2.50, 1.85)	EPI-LSE																	
-1.55 (-3.43, 0.33)	-1.33 (-3.52, 0.86)	-0.80 (-2.39, 0.79)	-0.40 (-2.29, 1.50)	-0.07 (-1.96, 1.82)	AV-eLS																
-1.75 (-3.94, 0.43)	-1.53 (-4.00, 0.93)	-1.00 (-2.95, 0.94)	-0.60 (-2.44, 1.24)	-0.27 (-2.47, 1.92)	-0.20 (-2.12, 1.71)	AV+AE-iLS															
-1.85 (-3.73, 0.03)	-1.63 (-3.82, 0.56)	-1.10 (-2.68, 0.48)	-0.70 (-2.58, 1.19)	-0.37 (-1.45, 0.71)	-0.30 (-1.84, 1.24)	-0.10 (-2.00, 1.81)	AV+SR														
-2.01 (-4.06, 0.03)	-1.79 (-4.13, 0.54)	-1.26 (-3.04, 0.51)	-0.86 (-2.52, 0.80)	-0.53 (-2.58, 1.51)	-0.46 (-2.21, 1.28)	-0.26 (-1.95, 1.43)	-0.16 (-1.90, 1.57)	AV+AE-cLSC													
-1.95 (-3.48, -0.42)	-1.73 (-3.63, 0.17)	-1.20 (-2.35, -0.05)	-0.80 (-2.34, 0.74)	-0.47 (-2.00, 1.06)	-0.40 (-1.50, 0.70)	-0.20 (-1.76, 1.37)	-0.10 (-1.19, 0.99)	0.06 (-1.29, 1.42)	AV												
-1.99 (-3.78, -0.20)	-1.77 (-3.88, 0.34)	-1.24 (-2.71, 0.23)	-0.83 (-2.43, 0.76)	-0.51 (-2.30, 1.28)	-0.44 (-1.87, 0.99)	-0.23 (-1.85, 1.38)	-0.14 (-1.56, 1.28)	0.03 (-1.39, 1.44)	-0.04 (-0.96, 0.88)	AV+AE-pv											
-2.85 (-4.60, -1.11)	-2.63 (-4.72, -0.55)	-2.10 (-3.53, -0.68)	-1.70 (-2.99, -0.41)	-1.37 (-3.13, 0.38)	-1.30 (-2.69, 0.08)	-1.10 (-2.42, 0.22)	-1.00 (-2.38, 0.37)	-0.84 (-1.90, 0.22)	-0.90 (-1.75, -0.06)	-0.87 (-1.80, 0.07)	AV+AE										

Network league tables for all the PHN prevention strategies regarding (A) Incidence of PHN at 3 mo, (B) Incidence of PHN at 1 months, (C) Incidence of PHN at 6 mo, (D) Mean pain score at 3 mo and (E) Mean pain score at 1 mo. Estimates are presented as mean difference (95% confidence interval).

Supplementary Table 2. Network diagnostic for Bayesian analysis.

	Model	Dbar	pD	DIC	PSRF	I ² (%)
Incidence of postherpetic neuralgia at 3 mo after acute herpes zoster	Fixed	67.03	43.30	110.33	1.02	15%
	Random	60.13	49.24	109.37	1.01	5%
Incidence of postherpetic neuralgia at 1 mo after acute herpes zoster	Fixed	55.44	34.05	89.49	1.02	24%
	Random	46.50	39.81	86.31	1.01	10%
Incidence of postherpetic neuralgia at 6 mo after acute herpes zoster	Fixed	44.53	33.25	77.78	1.02	15%
	Random	39.86	36.22	76.09	1.01	5%
Pain score measured at 3 mo after acute herpes zoster	Fixed	16.78	15.32	32.10	1.00	11%
	Random	15.82	15.63	31.45	1.00	5%
Pain score measured at 1 mo after acute herpes zoster	Fixed	32.74	23.95	56.69	1.01	24%
	Random	25.98	25.64	51.62	1.01	4%

Dbar: posterior mean of the deviance, pD: adequate number of parameters, DIC: deviance information criterion, sum of Dbar and pD, PSRF: Potential Scale Reduction Factor


Supplementary Table 3. Results of network meta-regression analysis

		95% CI	DIC_NMR	DIC_NM	I ² _NMR (%)	I ² _NM (%)
Incidence of postherpetic neuralgia at 3 mo after acute herpes zoster	ROB	-1.38 (-0.16 to 2.89)	106.95	109.37	3%	5%
	Age	-0.23 (-1.34 to 0.87)	110.52		5%	
	Sex(M)	-0.07(-1.38 to 1.12)	110.38		5%	
Incidence of postherpetic neuralgia at 1 mo after acute herpes zoster	ROB	1.83 (-0.21 to 3.85)	82.10	86.31	6%	10%
	Age	-0.58 (-1.99 to 0.69)	85.86		8%	
	Sex(M)	0.55 (-1.19 to 2.26)	86.47		9%	
Incidence of postherpetic neuralgia at 6 mo after acute herpes zoster	ROB	2.19 (-0.30 to 4.79)	74.21	76.09	1%	5%
	Age	-1.18 (-4.03 to 1.47)	76.53		5%	
	Sex(M)	1.86 (-0.78 to 4.76)	76.01		4%	
Pain score measured at 3 mo after acute herpes zoster	ROB	NP		31.45		5%
	Age	-0.28 (-4.52 to 3.32)	31.74		6%	
	Sex(M)	-0.43 (-2.83 to 1.76)	31.70		5%	
Pain score measured at 1 mo after acute herpes zoster	ROB	NP		51.62		4%
	Age	1.68 (-1.25 to 4.80)	52.05		5%	
	Sex(M)	0.34 (-1.68 to 2.36)	52.19		4%	

CI: credible interval, DIC: deviance information criterion, sum of Dbar and PD, M: male, NMR: network meta-regression, NM: network meta-analysis, NP: Did not perform meta-regression because all the studies included were graded as “some concern” or “high risk of bias”.


Supplementary Fig. 1B. The rankograms of the incidence of postherpetic neuralgia at 3 mo after acute herpes zoster

Profiles indicate the probabilities for treatments to assume any of the possible ranks. It is the probability that a given treatment ranks first, second, third, and so on, among all of the treatments evaluated in the NMA.




Supplementary Fig. 1C The cumulative ranking curves of the incidence of postherpetic neuralgia at 3 mo after acute herpes zoster


The profile indicates the sum of the probabilities from those ranked first, second, third, and so on. A higher cumulative ranking curve (surface of under cumulative ranking curve [SUCRA]) value is regarded as an improved result for an individual's intervention. When ranking treatments, the closer the SUCRA value is to 100%, the higher the treatment ranking is relative to all other treatments.




Supplementary Fig. 1D. Trace and density plot in fixed model for the incidence of post-herpetic neuralgia at 3 mo after acute herpes zoster




Trace of d.AV.AV_ENS




Density of d.AV.AV_ENS




Trace of d.AV.AV_iLS




Density of d.AV.AV_iLS




Trace of d.AV.AV_sLS




Density of d.AV.AV_sLS




Trace of d.AV.AV_SR




Density of d.AV.AV_SR




Trace of d.AV.CTR




Density of d.AV.CTR




Trace of d.AV.ENS




Density of d.AV.ENS




Trace of d.AV.RTx




Density of d.AV.RTx











Trace of d.AV.SR




Density of d.AV.SR







Supplementary Fig. 1E. trace and density plot in random model for the incidence of postherpetic neuralgia at 3 mo after acute herpes zoster




Trace of d.AV.AV_ENS




Density of d.AV.AV_ENS




Trace of d.AV.AV_iLS




Density of d.AV.AV_iLS




Trace of d.AV.AV_sLS




Density of d.AV.AV_sLS




Trace of d.AV.AV_SR




Density of d.AV.AV_SR




Trace of d.AV.CTR




Density of d.AV.CTR




Trace of d.AV.ENS




Density of d.AV.ENS




Trace of d.AV.RTx




Density of d.AV.RTx











Trace of d.AV.SR




Density of d.AV.SR







Trace of sd.d










Density of sd.d












Supplementary Fig 1E. Gelman-Rubin-Brooks in fixed model for the incidence of postherpetic neuralgia at 3 mo after acute herpes zoster






Supplementary Fig. 1G. Gelman-Rubin-Brooks in random model for the incidence of postherpetic neuralgia at 3 mo after acute herpes zoster






Supplementary Fig. 2B. The rankograms of the incidence of postherpetic neuralgia at 1 mo after acute herpes zoster

Profiles indicate the probabilities for treatments to assume any of the possible ranks. It is the probability that a given treatment ranks first, second, third, and so on, among all of the treatments evaluated in the NMA.












Supplementary Fig. 2C. The cumulative ranking curves of the incidence of postherpetic neuralgia at 1 mo after acute herpes zoster









The profile indicates the sum of the probabilities from those ranked first, second, third, and so on. A higher cumulative ranking curve (surface of under cumulative ranking curve [SUCRA]) value is regarded as an improved result for an individual's intervention. When ranking treatments, the closer the SUCRA value is to 100%, the higher the treatment ranking is relative to all other treatments.




Supplementary Fig. 2D. Trace and density plot in fixed model for the incidence of postherpetic neuralgia at 1 mo after acute herpes zoster









Trace of d.CTR.ACTH




Density of d.CTR.ACTH




Trace of d.CTR.VZVIG



















Density of d.CTR.VZVIG




Supplementary Fig. 2E. trace and density plot in random model for the incidence of postherpetic neuralgia at 1 mo after acute herpes zoster









Trace of d.CTR.ACTH




Density of d.CTR.ACTH




Trace of d.CTR.VZVIG




Density of d.CTR.VZVIG




Trace of sd.d




Density of sd.d




Supplementary Fig. 2F. Gelman-Rubin-Brooks in fixed model for the incidence of postherpetic neuralgia at 1 mo after acute herpes zoster




d.AV.CTR




d.AV.ENS




d.AV_SR.EPI_LSE




d.CTR.ACTH




d.CTR.VZVIG




Supplementary Fig. 2G. Gelman-Rubin-Brooks in random model for the incidence of postherpetic neuralgia at 1 mo after acute herpes zoster




d.AV.CTR




d.AV.ENS




d.AV_SR.EPI_LSE




d.CTR.ACTH



d.CTR.VZVIG




sd.d




Supplementary Fig. 3B. The rankograms of the incidence of postherpetic neuralgia at 6 mo after acute herpes zoster

Profiles indicate the probabilities for treatments to assume any of the possible ranks. It is the probability that a given treatment ranks first, second, third, and so on, among all of the treatments evaluated in the NMA.




Supplementary Fig. 3C. The cumulative ranking curves of the incidence of postherpetic neuralgia at 6 mo after acute herpes zoster


The profile indicates the sum of the probabilities from those ranked first, second, third, and so on. A higher cumulative ranking curve (surface of under cumulative ranking curve [SUCRA]) value is regarded as an improved result for an individual's intervention. When ranking treatments, the closer the SUCRA value is to 100%, the higher the treatment ranking is relative to all other treatments.




Supplementary Fig. 3D. Trace and density plot in fixed model for the incidence of postherpetic neuralgia at 6 month after acute herpes zoster




Trace of d.AV.AV_ENS




Density of d.AV.AV_ENS




Trace of d.AV.AV_iLS




Density of d.AV.AV_iLS




Trace of d.AV.AV_sLS




Density of d.AV.AV_sLS




Trace of d.AV.AV_SR




Density of d.AV.AV_SR




Trace of d.AV.CTR




Density of d.AV.CTR




Trace of d.AV.ENS




Density of d.AV.ENS




Trace of d.AV.RTx




Density of d.AV.RTx











Trace of d.AV.SR




Density of d.AV.SR







Supplementary Fig. 3E. trace and density plot in random model for the incidence of postherpetic neuralgia at 6 mo after acute herpes zoster




Trace of d.AV.AV_ENS




Density of d.AV.AV_ENS




Trace of d.AV.AV_iLS




Density of d.AV.AV_iLS




Trace of d.AV.AV_sLS




Density of d.AV.AV_sLS




Trace of d.AV.AV_SR




Density of d.AV.AV_SR




Trace of d.AV.CTR




Density of d.AV.CTR




Trace of d.AV.ENS




Density of d.AV.ENS




Trace of d.AV.RTx




Density of d.AV.RTx




Trace of d.AV.SR




Density of d.AV.SR




Trace of d.AV_AE.AV_AE_cLSC




Density of d.AV_AE.AV_AE_cLSC




Trace of d.AV_AE.AV_AE_iLS




Density of d.AV_AE.AV_AE_iLS




Trace of d.AV_AE.AV_AE_sgLS




Density of d.AV_AE.AV_AE_sgLS




Trace of d.AV_SR.EPI_LSE




Density of d.AV_SR.EPI_LSE




Trace of sd.d










Density of sd.d












Supplementary Fig. 3F. Gelman-Rubin-Brooks in fixed model for the incidence of postherpetic neuralgia at 6 mo after acute herpes zoster






Supplementary Fig. 3G. Gelman-Rubin-Brooks in random model for the incidence of postherpetic neuralgia at 6 mo after acute herpes zoster






Supplementary Fig. 4A. Predictive Interval Plot comparing all groups for the pain score measured at 3 mo after acute herpes zoster




Supplementary Fig. 4B. The rankograms of the pain score measured at 3 mo after acute herpes zoster

Profiles indicate the probabilities for treatments to assume any of the possible ranks. It is the probability that a given treatment ranks first, second, third, and so on, among all of the treatments evaluated in the NMA.




Supplementary Fig. 4C. The cumulative ranking curves of the pain score measured at 3 mo after acute herpes zoster


The profile indicates the sum of the probabilities from those ranked first, second, third, and so on. A higher cumulative ranking curve (surface of under cumulative ranking curve [SUCRA]) value is regarded as an improved result for an individual's intervention. When ranking treatments, the closer the SUCRA value is to 100%, the higher the treatment ranking is relative to all other treatments.




Supplementary Fig. 4D. Trace and density plot in fixed model for the pain score measured at 3 mo after acute herpes zoster




Trace of d.AV_AE.AV_AE_cLSC




Density of d.AV_AE.AV_AE_cLSC




Trace of d.AV_AE.AV_AE_iLS




Density of d.AV_AE.AV_AE_iLS




Trace of d.AV_AE.AV_AE_sgLS




Density of d.AV_AE.AV_AE_sgLS




Supplementary Fig. 4E. trace and density plot in random model for the pain score measured at 3 mo after acute herpes zoster




Trace of d.AV_AE.AV_AE_cLSC




Density of d.AV_AE.AV_AE_cLSC




Trace of d.AV_AE.AV_AE_iLS




Density of d.AV_AE.AV_AE_iLS




Trace of d.AV_AE.AV_AE_sgLS




Density of d.AV_AE.AV_AE_sgLS




Trace of sd.d




Density of sd.d




Supplementary Fig. 4F. Gelman-Rubin-Brooks in fixed model for the pain score measured at 3 mo after acute herpes zoster



Supplementary Fig. 4G. Gelman-Rubin-Brooks in random model for the pain score measured at 3 mo after acute herpes zoster




Supplementary Fig. 5A. Predictive Interval Plot comparing all groups for the pain score measured at 1 mo after acute herpes zoster




Supplementary Fig. 5B. The rankograms of the pain score measured at 1 mo after acute herpes zoster

Profiles indicate the probabilities for treatments to assume any of the possible ranks. It is the probability that a given treatment ranks first, second, third, and so on, among all of the treatments evaluated in the NMA.




Supplementary Fig. 5C. The cumulative ranking curves of the pain score measured at 1 mo after acute herpes zoster


The profile indicates the sum of the probabilities from those ranked first, second, third, and so on. A higher cumulative ranking curve (surface of under cumulative ranking curve [SUCRA]) value is regarded as an improved result for an individual's intervention. When ranking treatments, the closer the SUCRA value is to 100%, the higher the treatment ranking is relative to all other treatments.




Supplementary Fig. 5D. Trace and density plot in fixed model for the pain score measured at 1 mo after acute herpes zoster




Trace of d.AV.AV_iLS




Density of d.AV.AV_iLS




Trace of d.AV.AV_sgL




Density of d.AV.AV_sgL




Trace of d.AV.AV_SR




Density of d.AV.AV_SR




Trace of d.AV.ENS




Density of d.AV.ENS




Trace of d.AV_AE.AV_AE_cLSC




Density of d.AV_AE.AV_AE_cLSC




Trace of d.AV_AE.AV_AE_iLS




Density of d.AV_AE.AV_AE_iLS




Trace of d.AV_AE.AV_AE_sgLS




Density of d.AV_AE.AV_AE_sgLS




Trace of d.AV_SR.EPI_LSE




Density of d.AV_SR.EPI_LSE




Supplementary Fig. 5E. trace and density plot in random model for the pain score measured at 1 mo after acute herpes zoster




Trace of d.AV.AV_iLS




Density of d.AV.AV_iLS




Trace of d.AV.AV_sgL




Density of d.AV.AV_sgL




Trace of d.AV.AV_SR




Density of d.AV.AV_SR




Trace of d.AV.ENS




Density of d.AV.ENS




Trace of d.AV_AE.AV_AE_cLSC




Density of d.AV_AE.AV_AE_cLSC




Trace of d.AV_AE.AV_AE_iLS




Density of d.AV_AE.AV_AE_iLS




Trace of d.AV_AE.AV_AE_sgLS




Density of d.AV_AE.AV_AE_sgLS




Trace of d.AV_SR.EPI_LSE




Density of d.AV_SR.EPI_LSE




Trace of sd.d








Density of sd.d




Supplementary Fig. 5F. Gelman-Rubin-Brooks in fixed model for the pain score measured at 1 mo after acute herpes zoster







Supplementary Fig. 5G. Gelman-Rubin-Brooks in random model for the pain score measured at 1 mo after acute herpes zoster




d.AV.ENS




d.AV_AE.AV_AE_cLSC




d.AV_AE.AV_AE_iLS



d.AV_AE.AV_AE_sgLS



d.AV_SR.EPI_LSE



sd.d

